[Simvastatin in management of patients with primary hypercholesterolemia: tolerability and efficacy of daily doses 10-80 mg]. 2002

A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk

OBJECTIVE To analyze retrospectively data on lipid lowering efficacy, tolerability and safety of different doses of simvastatin in patients with primary hyperlipidemia. METHODS Thirty five patients (mean age 54.9-/+8.5 years, 15 men, 20 women) received simvastatin for 3-6 months in doses 10 (n=12), 20 (n=8), 40 (n=10) and 80 (n=5) mg/day. Average lowering of low density lipoprotein cholesterol was 28.9, 37.6, 39.7, and 46.2% on doses 10, 20, 40 and 80 mg/day, respectively. Elevation of activity of transaminases (AST and ALT) above 3 upper limits of normal (ULN) accompanied by right upper quadrant pain occurred in 1 patient and the drug (10 mg/day) was stopped. Symptomless elevation of AST and ALT activities above 2 ULN was registered in 2 other patients receiving 10 and 20 mg/day. The dose of 80 mg/day was well tolerated - none of 5 patients had symptoms of myopathy or elevated creatinekinase activity.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol
D000924 Anticholesteremic Agents Substances used to lower plasma CHOLESTEROL levels. Cholesterol Inhibitors,Hypocholesteremic Agents,Anticholesteremic Drugs,Anticholesteremics,Inhibitors, Cholesterol,Agents, Anticholesteremic,Agents, Hypocholesteremic,Drugs, Anticholesteremic
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019821 Simvastatin A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL. MK-733,Synvinolin,Zocor,MK 733,MK733

Related Publications

A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
December 1989, Schweizerische medizinische Wochenschrift,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
January 1994, Cardiology,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
January 1993, Acta cardiologica,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
January 1991, Clinical therapeutics,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
August 2005, Journal of the Chinese Medical Association : JCMA,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
January 1997, The American journal of cardiology,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
October 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
February 1994, International journal of clinical pharmacology and therapeutics,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
December 2007, Ginekologia polska,
A V Susekov, and E Iu Solov'eva, and T A Rozhkova, and L A Kotova, and Z A Akhmedova, and V V Kukharchuk
June 1996, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!